Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701042 | 0.88 | AR (0.44) | ARHTR6ALDH1A1LMNAHTT | |
| SCHEMBL14688617 | 0.82 | HTR6 (0.36) | HTR6ALDH1A1LMNASMN1; SMN2PTGS1 | |
| SCHEMBL2358789 | 0.78 | HTR6 (0.35) | HTR6ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL14701016 | 0.77 | AR (0.44) | ARHTR6ALDH1A1LMNAHTT | |
| SCHEMBL2360445 | 0.77 | HTR6 (0.42) | HTR6ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL2359831 | 0.75 | HTR6 (0.38) | ARHTR6ALDH1A1LMNAHTT | |
| SCHEMBL2359943 | 0.75 | HTR6 (0.38) | HTR6ALDH1A1LMNAPTGS1PTGS2 | |
| SCHEMBL18804022 | 0.75 | AR (0.45) | ARHTR6ALDH1A1LMNAHTT | |
| SCHEMBL2360380 | 0.74 | HTR6 (0.35) | ARHTR6ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14702106 | 0.72 | AR (0.41) | ARHTR6ALDH1A1LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121285-A1 | Selective androgen receptor modulators | AR, SHBG, FSHR | AR 1/4885HTR6 544/4885ALDH1A1 1511/4885 |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | AR 1/4885HTR6 683/4885ALDH1A1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.